Small Molecule Inhibitors of Dusp6 and Uses Therefor

US2016355459A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016355459-A1
Application numberUS-201615243089-A
CountryUS
Kind codeA1
Filing dateAug 22, 2016
Priority dateMar 20, 2009
Publication dateDec 8, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound having the formula: in which R1 represents one or more independently of H, halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; R2 is a a secondary or tertiary amine group; R3 is one or more independently of H, halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; and R4 is ═O or —OH, wherein when both R1 and R3 are H, R4 is —OH, or R3 is one or more independently of halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN, and when R1 is H and R4 is ═O, R3 is one or more independently of halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN, or a pharmaceutically-acceptable salt thereof. 2 . The compound of claim 1 in which R2 is a C 4-10 cycloalkylamine. 3 . The compound of claim 1 in which R2 is one of cyclopentylamine and cycloheptylamine. 4 . The compound of claim 1 consisting essentially of a (−) enantiomer of the compound. 5 . The compound of claim 1 having the formula: 6 . The compound of claim 1 in which R4 is ═O. 7 . The compound of claim 6 in which R2 is one of 4-t-Boc-cyclohexylamine, thiamorpholine, piperazine, methyl piperazine, acetyl piperazine, cyclopentylamine, cycloheptylamine and di-C 1-4 -alkylamine. 8 . The compound of claim 1 in which R4 is —OH. 9 . The compound of claim 1 , wherein R1 is 3,4-di-halo. 10 . The compound of claim 1 , wherein R1 is 3,4-dichloro. 11 . The compound of claim 1 , wherein R2 is one of C 4-10 cycloalkylamine, 4-t-Boc-cyclohexylamine, thiamorpholine, piperazine, methyl piperazine, acetyl piperazine, phenylamine, piperidine, morpholine, biotin, and di-C 1-4 -alkylamine. 12 . A composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable excipient. 13 . A method of inhibiting dual specificity phosphatase 6 (Dusp6)-induced dephosphorylation of extracellular signal-related kinase (ERK), comprising contacting a cell with a compound having the formula: in which R1 represents one or more independently of H, halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; R2 is a secondary or tertiary amine group; R3 is one or more independently of H, halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; and R4 is ═O or —OH, wherein when both R1 and R3 are H, R4 is —OH, or R3 is one or more independently of halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN, and when R1 is H and R4 is ═O, R3 is one or more independently of halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN, or a pharmaceutically-acceptable salt thereof, in an amount effective to inhibit dephosphorylation of ERK by Dusp6. 14 . The method of claim 13 , wherein R3 is halo. 15 . The method of claim 14 , where R3 is Br. 16 . The method of claim 13 , wherein R2 is a C 4-10 cycloalkylamine. 17 . The method of claim 13 , wherein R2 is one of cyclopentylamine and cycloheptylamine. 18 . The method of claim 13 , wherein R1 is H, R2 is one of cyclopentylamine, cyclohexylamine, and cycloheptylamine, and R3 is Br. 19 . The method of claim 18 , wherein R2 is cyclohexylamine. 20 . The method of claim 13 , wherein the compound has the structure:

Assignees

Inventors

Classifications

  • having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title

  • C07D495/04Primary

    Ortho-condensed systems · CPC title

  • C07C225/20Primary

    having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton · CPC title

  • with six-membered aromatic rings being part of the condensed ring systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016355459A1 cover?
Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.
Who is the assignee on this patent?
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
What technology area does this patent fall under?
Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Dec 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).